Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by Dwizellon Oct 04, 2018 9:05am
172 Views
Post# 28743308

RE:RE:Luc maintains Trogarzo peak sales potential 4X or 5X EGRIFTA

RE:RE:Luc maintains Trogarzo peak sales potential 4X or 5X EGRIFTAIt's not the way I see it ....

He said Eggrifta will increase 15% a year (because of f 4) in the next years ... so in five years it will reach something like near 100 million in sales ...  so 5 time is 5 millions in line with the initial expectations.

And he said we will beat Egrifta sales in the first year of Trogarzo sales ,,, meaning arround 55 to 60 millions as of april 30th. We are at 6 now with 8 mounths remaining ... so we will have 50 millions of sales form spetember first  to april 30th .. I think it's clear enough perspective ... 

And indeed for Europe it's not clear if he included those figures ... my guess is no ... but I could be wrong ...
Bullboard Posts